La Jolla Pharmaceutical Company

NasdaqCM:LJPC Stock Report

Mkt Cap: US$155.1m

La Jolla Pharmaceutical Past Performance

How has La Jolla Pharmaceutical performed over the past 5 years?

Past Performance Score

2/6

Past Performance Score 2/6

  • Quality Earnings

  • Growing Profit Margin

  • Earnings Trend

  • Accelerating Growth

  • Earnings vs Industry

  • High ROE


40.6%

Historical annual earnings growth

Earnings and Revenue History

Quality Earnings: LJPC has a large one-off gain of $2.3M impacting its June 30 2022 financial results.

Growing Profit Margin: LJPC's current net profit margins (8.5%) are higher than last year (4.1%).


Past Earnings Growth Analysis

Earnings Trend: LJPC has become profitable over the past 5 years, growing earnings by 40.6% per year.

Accelerating Growth: LJPC's earnings growth over the past year (36.3%) is below its 5-year average (40.6% per year).

Earnings vs Industry: LJPC earnings growth over the past year (36.3%) underperformed the Biotechs industry 53%.


Return on Equity

High ROE: LJPC's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.


Return on Assets


Return on Capital Employed


Discover strong past performing companies